Compare Bristol-Myers Squibb Co (BMY) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Zscaler Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.53 (market cap $116.30B), while Zscaler Inc trades at $148.51 (market cap $24.59B). The key difference: Bristol-Myers Squibb Co is far larger — about 4.7× Zscaler Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| BMY | ZS | |
|---|---|---|
Market Cap | $116.30B | $24.59B |
Sector | Health | Technology |
52-Week High | $62.37 | $336.27 |
52-Week Low | $42.60 | $118.05 |
Enterprise Value | $152.24B | $22.92B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Zscaler trades at $141.82, up 1.83% with bearish technical signals despite recent earnings beats. Revenue growth remains strong at $2.67B for 2025, though the company continues to report net losses. Analyst consensus is overwhelmingly bullish with a $192.64 price target, but multiple class action investigations and high valuation metrics create headwinds.
The stock faces near-term pressure from technical weakness and profitability challenges, but long-term prospects remain supported by cybersecurity demand and Zero Trust adoption. Key risks include ongoing litigation, AI infrastructure costs, and the transition to profitability amid slowing growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
